SOX2 and glioma: In glial tumors, growth, angiogenesis, and therapeutic resistance itself are supported by glioma stem cells in which hypoxia upregulated the expression of stemness markers (CD133, OCT4, SOX2) and promoted CD133 glycosylation, which may play a role in the hypoxia-mediated anti-apoptosis process.